Dasatinib

Name: Dasatinib
Brand: Selleck Chemicals
SKU: S1021
Rating: 5 (277 reviews)

For research use only.

Catalog No.S1021 Synonyms: BMS-354825

277 publications

Molecular Weight(MW): 488.01

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively. Dasatinib induces autophagy and apoptosis with anti-tumor activity.

Selleck's Dasatinib has been cited by 277 publications

Cell Stem Cell, 2020, 10;S1934-5909(20)30144-2

PubMed: 32413332 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nat Immunol, 2018, 19(6):561-570

PubMed: 29777213 ( click the link to review the publication )

Nature, 2017, 543(7647):728-732

PubMed: 28321130 ( click the link to review the publication )

Nat Med, 2017, 23(3):291-300

PubMed: 28191885 ( click the link to review the publication )

Nat Med, 2017, 23(12):1424-1435

PubMed: 29131160 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Cancer Cell, 2016, 29(4):563-573

PubMed: 27070703 ( click the link to review the publication )

Nat Genet, 2014, 46(2):166-70

PubMed: 24413734 ( click the link to review the publication )

Cell, 2012, 21;151(7):1457-73.

PubMed: 23245941 ( click the link to review the publication )

Cell Stem Cell, 2012, 10(2):210-7

PubMed: 22305570 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Blood, 2020, 8 pii: blood

PubMed: 32270193 ( click the link to review the publication )

Cell Res, 2020, 27;1-16

PubMed: 32341413 ( click the link to review the publication )

Mol Cell, 2020, 7;S1097-2765(20)30269-0

PubMed: 32416067 ( click the link to review the publication )

J Clin Invest, 2020, 1;130(4):1879-1895

PubMed: 31874105 ( click the link to review the publication )

Leukemia, 2020, 14

PubMed: 32409689 ( click the link to review the publication )

Neuro Oncol, 2020, 15;22(4):493-504

PubMed: 31883012 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Cancer Res, 2020, 30 pii: canres

PubMed: 32354737 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Cell Rep, 2020, 24;30(12):3951-3963 e4

PubMed: 32209458 ( click the link to review the publication )

Cell Rep, 2020, 30(3):793-806

PubMed: 31968254 ( click the link to review the publication )
J Hematol Oncol, 2020, 13(1):80

PubMed: 32552902 ( click the link to review the publication )

Oncogene, 2020, 39(20):3980-3996

PubMed: 32238881 ( click the link to review the publication )

Oncogene, 2020, 39(2):308-321

PubMed: 31477830 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-1255-y

PubMed: 32157217 ( click the link to review the publication )

Oncogene, 2020, 39(20):4045-4060

PubMed: 32214198 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 25;12(5)

PubMed: 32344828 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Cancers (Basel), 2020, 31;12(4) pii: E841

PubMed: 32244515 ( click the link to review the publication )

Cancers (Basel), 2020, 26;12(4)

PubMed: 32224911 ( click the link to review the publication )

PLoS Pathog, 2020, 16;16(3):e1008341

PubMed: 32176725 ( click the link to review the publication )

Breast Cancer Res, 2020, 15;22(1):37

PubMed: 32295603 ( click the link to review the publication )

Cell Death Discov, 2020, 15;6:36

PubMed: 32435511 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0952-1

PubMed: 32572172 ( click the link to review the publication )

FASEB J, 2020, 34(3):3773-3791

PubMed: 31945226 ( click the link to review the publication )

Stem Cell Res Ther, 2020, 11(1):270

PubMed: 32631432 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Microb Cell Fact, 2020, 20;19(1):74

PubMed: 32197603 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.14980

PubMed: 32032474 ( click the link to review the publication )

Biochem Pharmacol, 2020, 30;177:113941

PubMed: 32240650 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Sci Rep, 2020, 6;10(1):4211

PubMed: 32144278 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Breast Cancer Res Treat, 2020, 179(2):337-347

PubMed: 31655920 ( click the link to review the publication )
Cell Signal, 2020, 70:109574

PubMed: 32084531 ( click the link to review the publication )

Molecules, 2020, 8;25(9) pii: E2220

PubMed: 32397330 ( click the link to review the publication )

Biomol Ther (Seoul), 2020, 9

PubMed: 32268657 ( click the link to review the publication )

SLAS Discov, 2020, 19;2472555220915851

PubMed: 32425084 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2020, 1864(4):129507

PubMed: 31881245 ( click the link to review the publication )

bioRxiv, 2020, 2020/9/20.4.7.30734

PubMed: 32511305 ( click the link to review the publication )

Commun Biol, 2020, 3(1):18

PubMed: 31925328 ( click the link to review the publication )

J Exp Med, 2020, 217(2)

PubMed: 31704808 ( click the link to review the publication )

Cells, 2020, 9(2)

PubMed: 32102381 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Am J Respir Crit Care Med, 2019, 101164/rccm201902-0451OC

PubMed: 31738079 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2556

PubMed: 31186408 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1515

PubMed: 30944303 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-2309

PubMed: 31857430 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(16):5038-5048

PubMed: 31182436 ( click the link to review the publication )

Cancer Res, 2019, 79(1):209-219

PubMed: 30389701 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2019.215939

PubMed: 31289206 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1104

PubMed: 31585938 ( click the link to review the publication )

Mol Syst Biol, 2019, 15(3):e8323

PubMed: 30858180 ( click the link to review the publication )

Cancer Res, 2019, 79(13):3306-3319

PubMed: 31101761 ( click the link to review the publication )

Theranostics, 2019, 9(7):1952-1964

PubMed: 31037149 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Thyroid, 2019, 29(3):395-404

PubMed: 30724135 ( click the link to review the publication )

Oncogene, 2019, 38(12):2135-2150

PubMed: 30459358 ( click the link to review the publication )
Stem Cell Reports, 2019, 10.1016/j.stemcr.2019.08.005

PubMed: 31522974 ( click the link to review the publication )

Br J Cancer, 2019, 121(7):567-577

PubMed: 31474759 ( click the link to review the publication )

J Clin Med, 2019, 8(8)

PubMed: 31382448 ( click the link to review the publication )

Cancer Discov, 2019, 9(6):756-777

PubMed: 30862724 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0449

PubMed: 31744897 ( click the link to review the publication )

J Physiol, 2019, 597(6):1627-1642

PubMed: 30488437 ( click the link to review the publication )

Mol Biol Cell, 2019, 30(9):1108-1117

PubMed: 30785867 ( click the link to review the publication )

Sci Rep, 2019, 9(1):4819

PubMed: 30894630 ( click the link to review the publication )

Sci Rep, 2019, 9(1):7617

PubMed: 31110200 ( click the link to review the publication )

Sci Rep, 2019, 9(1):17171

PubMed: 31748572 ( click the link to review the publication )

Nanomaterials (Basel), 2019, 9(12)

PubMed: 31888247 ( click the link to review the publication )

J Proteome Res, 2019, 18(1):522-534

PubMed: 30540191 ( click the link to review the publication )

J Pharmacol Exp Ther, 2019, 369(3):531-545

PubMed: 30898866 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):485

PubMed: 31118072 ( click the link to review the publication )

Molecules, 2019, 24(3)

PubMed: 30754629 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2019, 9:80-86

PubMed: 30771616 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2019, 84(6):1241-1256

PubMed: 31541266 ( click the link to review the publication )

PLoS One, 2019, 14(2):e0212210

PubMed: 30779812 ( click the link to review the publication )

PLoS One, 2019, 14(2):e0212860

PubMed: 30794695 ( click the link to review the publication )

Leuk Lymphoma, 2019, 60(1):189-199

PubMed: 29741440 ( click the link to review the publication )

Environ Mol Mutagen, 2019, 60(6):513-533

PubMed: 30702769 ( click the link to review the publication )

Leuk Res, 2019, 78:12-20

PubMed: 30660961 ( click the link to review the publication )

J Immunol Methods, 2019, 464:22-30

PubMed: 30347189 ( click the link to review the publication )

Oncotarget, 2019, 10(31):2930-2946

PubMed: 31105876 ( click the link to review the publication )
Oncotarget, 2019, 10(23):2237-2251

PubMed: 31040916 ( click the link to review the publication )

J Extracell Vesicles, 2019, 9(1):1698889

PubMed: 31853340 ( click the link to review the publication )

Nat Neurosci, 2019, 22(5):719-728

PubMed: 30936558 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):37-60

PubMed: 30836148 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Sci Transl Med, 2018, 10(427)

PubMed: 29437150 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1523

PubMed: 29670076 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(26):E6030-E6038

PubMed: 29875142 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):85

PubMed: 29925404 ( click the link to review the publication )

Oncogene, 2018, 37(16):2104-2121

PubMed: 29379163 ( click the link to review the publication )

Oncogene, 2018, 37(21):2837-2849

PubMed: 29511345 ( click the link to review the publication )

Cell Mol Life Sci, 2018, 75(22):4223-4234

PubMed: 29955905 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459283 ( click the link to review the publication )

Sci Signal, 2018, 11(539)

PubMed: 30018082 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):183

PubMed: 30081903 ( click the link to review the publication )

EBioMedicine, 2018, 29:112-127

PubMed: 29433983 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30572654 ( click the link to review the publication )

Cell Commun Signal, 2018, 16(1):21

PubMed: 29776413 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(10):1556-1567

PubMed: 29903769 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(7)

PubMed: 30036966 ( click the link to review the publication )

Sci Rep, 2018, 8(1):5362

PubMed: 29599515 ( click the link to review the publication )

Food Chem Toxicol, 2018, 119:464-478

PubMed: 29097117 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )
Front Pharmacol, 2018, 9:403

PubMed: 29765318 ( click the link to review the publication )

Front Pharmacol, 2018, 9:1285

PubMed: 30473665 ( click the link to review the publication )

Int J Oncol, 2018, 52(6):2061-2068

PubMed: 29620253 ( click the link to review the publication )

Cytokine, 2018, 111:209-215

PubMed: 30176559 ( click the link to review the publication )

Cell Adh Migr, 2018, 12(3):286-298

PubMed: 28678601 ( click the link to review the publication )

Toxicol Lett, 2018, 296:39-47

PubMed: 30086328 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

FEBS Open Bio, 2018, 8(5):732-742

PubMed: 29744288 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Oncotarget, 2018, 9(12):10723-10733

PubMed: 29535838 ( click the link to review the publication )

Oncoscience, 2018, 5(1-2):21-38

PubMed: 29556515 ( click the link to review the publication )

Nature, 2018, 563(7730):265-269

PubMed: 30401838 ( click the link to review the publication )

Sci Transl Med, 2017, 9(374)

PubMed: 28123069 ( click the link to review the publication )

Sci Transl Med, 2017, 9(414)10

PubMed: 29093181 ( click the link to review the publication )

Blood, 2017, 129(11):e26-e37

PubMed: 28122742 ( click the link to review the publication )

Mol Cell, 2017, 66(5):635-647

PubMed: 28575659 ( click the link to review the publication )

Nat Commun, 2017, 1;8(1):1232

PubMed: 29089541 ( click the link to review the publication )

Nat Commun, 2017, 8:14073

PubMed: 28102225 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(23):7360-7374

PubMed: 28939749 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28199182 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.25946

PubMed: 28598329 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):118

PubMed: 28606127 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2387-2398

PubMed: 28775147 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1729-1738

PubMed: 28619758 ( click the link to review the publication )
Neoplasia, 2017, 19(4):354-363

PubMed: 28319809 ( click the link to review the publication )

Toxicol Sci, 2017, 162(1):146-166

PubMed: 29106658 ( click the link to review the publication )

J Biol Chem, 2017, 292(35):14381-14390

PubMed: 28684419 ( click the link to review the publication )

Cancer Med, 2017, 6(4):809-818

PubMed: 28316141 ( click the link to review the publication )

J Appl Toxicol, 2017, 37(3):382-390

PubMed: 27480533 ( click the link to review the publication )

Clin Res Hepatol Gastroenterol, 2017, 41(6):677-686

PubMed: 28578938 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:73-83

PubMed: 28123301 ( click the link to review the publication )

J Neurophysiol, 2017, 118(1):595-609

PubMed: 28446585 ( click the link to review the publication )

Eur J Haematol, 2017, 99(5):442-448

PubMed: 28881484 ( click the link to review the publication )

Arch Pharm Res, 2017, 40(2):197-203

PubMed: 27988882 ( click the link to review the publication )

Mol Vis, 2017, 23:823-831

PubMed: 29225458 ( click the link to review the publication )

SLAS Discov, 2017, 22(7):915-922

PubMed: 28346107 ( click the link to review the publication )

Ther Drug Monit, 2017, 39(3):252-262

PubMed: 28490048 ( click the link to review the publication )

Cell Death Dis, 2017, 8(8):e3029

PubMed: 29048432 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):233-246

PubMed: 27989769 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90262-90277

PubMed: 29163826 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(8):1903-1913

PubMed: 27931141 ( click the link to review the publication )

Hepatology, 2017, 66(6):1934-1951

PubMed: 28714104 ( click the link to review the publication )

Oncotarget, 2017, 8(47):81794-81802

PubMed: 29137222 ( click the link to review the publication )

Blood Adv, 2017, 1(26):2610-2623

PubMed: 29296914 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(6):754-768

PubMed: 28618271 ( click the link to review the publication )

Oncotarget, 2017, 8(43):73871-73883

PubMed: 29088753 ( click the link to review the publication )

Nat Commun, 2016, 7:10060

PubMed: 26725982 ( click the link to review the publication )

Nat Commun, 2016, 7:11889

PubMed: 27297662 ( click the link to review the publication )
Nat Commun, 2016, 7:12428

PubMed: 27687249 ( click the link to review the publication )

EMBO Mol Med, 2016, 1;8(2):105-16

PubMed: 26758680 ( click the link to review the publication )

Leukemia, 2016, 30(6):1273-81

PubMed: 26987906 ( click the link to review the publication )

Leukemia, 2016, 30(7):1493-501

PubMed: 27044711 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(51):E8228-E8237

PubMed: 27930322 ( click the link to review the publication )

Cancer Res, 2016, 76(12):3520-30

PubMed: 27197167 ( click the link to review the publication )

Int J Cancer, 2016, 139(10):2359-69

PubMed: 27434411 ( click the link to review the publication )

Cancer Lett, 2016, 376(1):188-96

PubMed: 26996299 ( click the link to review the publication )

Breast Cancer Res, 2016, 18(1):80

PubMed: 27495374 ( click the link to review the publication )

Development, 2016, 143(10):1674-87

PubMed: 26989177 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(5):819-29

PubMed: 26883271 ( click the link to review the publication )

J Infect Dis, 2016, 213(11):1767-76

PubMed: 26802142 ( click the link to review the publication )

Stem Cells Int, 2016, 2016:9601493

PubMed: 26788073 ( click the link to review the publication )

BMC Cancer, 2016, 16:229

PubMed: 26984511 ( click the link to review the publication )

PLoS One, 2016, 11(10):e0164895

PubMed: 27768734 ( click the link to review the publication )

Oncol Lett, 2016, 12(5):3598-3608

PubMed: 27900042 ( click the link to review the publication )

Assay Drug Dev Technol, 2016, 14(7):395-406

PubMed: 27552144 ( click the link to review the publication )

Oncotarget, 2016, 7(47):78083-78094

PubMed: 27801667 ( click the link to review the publication )

J Gen Virol, 2016, 97(5):1134-1144

PubMed: 26879209 ( click the link to review the publication )

Oncotarget, 2016, 7(37):59236-59244

PubMed: 27494860 ( click the link to review the publication )

Oncotarget, 2016, 7(18-:25983-6002

PubMed: 27036020 ( click the link to review the publication )

Sci Transl Med, 2015, 7(284):284ra57

PubMed: 25904741 ( click the link to review the publication )

Blood, 2015, 125(8):1282-91

PubMed: 25515960 ( click the link to review the publication )

Leukemia, 2015, 29(3):586-597

PubMed: 25134459 ( click the link to review the publication )
Cancer Lett, 2015, 10.1016/j.canlet.2015.02.044

PubMed: 25737303 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1767

PubMed: 25996294 ( click the link to review the publication )

Radiother Oncol, 2015, 116(3):431-7

PubMed: 26320552 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(1):262-8

PubMed: ( click the link to review the publication )

Eur Neuropsychopharmacol, 2015, 25(8):1275-86

PubMed: 25983018 ( click the link to review the publication )

J Cell Sci, 2015, 128(2):251-65

PubMed: ( click the link to review the publication )

Eur Neuropsychopharm, 2015, 10.1016/j.euroneuro.2015.04.021

PubMed: ( click the link to review the publication )

Biochem J, 2015, 465(2):271-9

PubMed: 25351958 ( click the link to review the publication )

Clin Immunol, 2015, 157(2):205-215

PubMed: 25728491 ( click the link to review the publication )

Neurotox Res, 2015, 27(4):384-98

PubMed: 25782580 ( click the link to review the publication )

Arch Biochem Biophys, 2015, 10.1016/j.taap.2015.03.018

PubMed: 25843419 ( click the link to review the publication )

PLoS One, 2015, 10(6):e0129663

PubMed: 26061184 ( click the link to review the publication )

Pulm Pharmacol Ther, 2015, 10.1016/j.pupt.2015.03.001

PubMed: 25843005 ( click the link to review the publication )

Leuk Res, 2015, 10.1016/j.leukres.2015.08.007

PubMed: 26346348 ( click the link to review the publication )

Mol Med Rep, 2015, 12(3):3249-3256

PubMed: 25975261 ( click the link to review the publication )

Int J Clin Exp Pathol, 2015, 8(7):7818-24

PubMed: 26339346 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: 25269544 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(4):557-62

PubMed: 25712742 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: ( click the link to review the publication )

Oncotarget, 2015, 6(4):1967-80

PubMed: 25596742 ( click the link to review the publication )

Eur J Pharm Sci, 2015, 80:56-65

PubMed: 26296860 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Oncotarget, 2015, 6(36):38854-65

PubMed: 26513174 ( click the link to review the publication )

J Virol, 2015, 90(4):1918-30

PubMed: 26656684 ( click the link to review the publication )
Oncotarget, 2015, 6(14):12405-20

PubMed: 25915159 ( click the link to review the publication )

Blood, 2014, 123(21):3296-304

PubMed: 24723681 ( click the link to review the publication )

Nat Commun, 2014, 5:3384

PubMed: 24594970 ( click the link to review the publication )

Leukemia, 2014, 28(10):2109-12

PubMed: 24919804 ( click the link to review the publication )

Cell Rep, 2014, 8(4):1037-48

PubMed: 25127139 ( click the link to review the publication )

Elife, 2014, 3:e02523

PubMed: 24844246 ( click the link to review the publication )

Cancer Lett, 2014, 344(1):90-100

PubMed: 24513268 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1023

PubMed: 24457967 ( click the link to review the publication )

Cell Death Dis, 2014, 6:e1595

PubMed: 25590805 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt 14):3039-51

PubMed: 24928894 ( click the link to review the publication )

Int J Mol Sci, 2014, 15(4):5838-51

PubMed: 24714091 ( click the link to review the publication )

Exp Cell Res, 2014, 328(1):20-31

PubMed: 25128812 ( click the link to review the publication )

J Pharm Biomed Anal, 2014, 94:125-31

PubMed: 24561338 ( click the link to review the publication )

PLoS One, 2014, 9(9):e107367

PubMed: 25198091 ( click the link to review the publication )

PLoS One, 2014, 9(1):e85485

PubMed: 24427313 ( click the link to review the publication )

Mol Biosyst, 2014, 10.1039/C4MB00224E

PubMed: 25099472 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )

Leuk Lymphoma, 2014, 10.3109/10428194.2014.898759

PubMed: 24597981 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Head Neck, 2014, 36(3):375-84

PubMed: 23729178 ( click the link to review the publication )

Graefes Arch Clin Exp Ophthalmol, 2014, 10.1007/s00417-014-2674-7

PubMed: 24874745 ( click the link to review the publication )

Mol Med Rep, 2014, 10(5):2729-35

PubMed: 25199623 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822.

PubMed: 24986420 ( click the link to review the publication )

Oncoscience, 2014, 1(1):57-68

PubMed: 25593988 ( click the link to review the publication )
J Exp Med, 2013, 210(11):2205-21

PubMed: 24127489 ( click the link to review the publication )

J Exp Med, 2013, 210(12):2569-82

PubMed: 24190431 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(18):5053-67

PubMed: 23900136 ( click the link to review the publication )

PLoS Biol, 2013, 11(3):e1001515

PubMed: 23526884 ( click the link to review the publication )

Cancer Lett, 2013, 340(1):43-50

PubMed: 23811285 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2013, 26(4):518-26

PubMed: 23582185 ( click the link to review the publication )

Neoplasia, 2013, 15(11):1272-81

PubMed: 24339739 ( click the link to review the publication )

J Thorac Cardiovasc Surg, 2013, 145(2):531-8

PubMed: 23142123 ( click the link to review the publication )

J Neurochem, 2013, 12(12):2864-73

PubMed: 24130049 ( click the link to review the publication )

J Biol Chem, 2013, 288(8):5553-61

PubMed: 23303179 ( click the link to review the publication )

Int J Oncol, 2013, 43(6):2064-72

PubMed: 24126464 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 72(1):35-44

PubMed: 23712327 ( click the link to review the publication )

Pharmgenomics Pers Med, 2013, 6:63-72

PubMed: 24019750 ( click the link to review the publication )

Sci Rep, 2013, 3:2100

PubMed: 23812503 ( click the link to review the publication )

Cell Cycle, 2013, 12(18):2978-91

PubMed: 23974111 ( click the link to review the publication )

Sci Transl Med, 2012, 4(136):136ra70

PubMed: 22649091 ( click the link to review the publication )

Blood, 2012, 119(21):4981-91

PubMed: 22411867 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(1):127-39

PubMed: 22090359 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(17):6584-10

PubMed: 22492965 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Br J Haematol, 2012, 157(4):510-4

PubMed: 22313359 ( click the link to review the publication )

J Virol, 2012, 86(16):8765-72

PubMed: 22696643 ( click the link to review the publication )

Angiogenesis, 2012, 15(1):33-45

PubMed: 22203239 ( click the link to review the publication )

Cancer Immunol Immun, 2012, 61(2):193-202

PubMed: 21874302 ( click the link to review the publication )
Invest New Drugs, 2012, 30(1):417-22

PubMed: 20953816 ( click the link to review the publication )

Stem Cells Dev, 2012, 21(16):2939-48

PubMed: 22642671 ( click the link to review the publication )

Hematol Oncol, 2012, 31(3):156-63

PubMed: 23108877 ( click the link to review the publication )

PLoS One, 2012, 7(7):e40853

PubMed: 22815843 ( click the link to review the publication )

J Biomol Screen, 2012, 18(4):388-99

PubMed: 23134735 ( click the link to review the publication )

J Liq Chromatogr R T, 2012, 2503-2510

PubMed: ( click the link to review the publication )

Cell Res, 2011, 21(7):1080-7

PubMed: 21423276 ( click the link to review the publication )

J Mol Biol, 2011, 411(2):474-85

PubMed: 21699901 ( click the link to review the publication )

J Virol, 2011, 85(5):2296-303

PubMed: 21177802 ( click the link to review the publication )

Cancer Prev Res , 2011, 4(8):1222-32

PubMed: 21546539 ( click the link to review the publication )

J Biol Chem, 2011, 286(16):13846-51

PubMed: 21343293 ( click the link to review the publication )

Exp Hematol, 2011, 39(8):859-65.e2

PubMed: 21689725 ( click the link to review the publication )

PLoS One, 2010, 5(11):e14143

PubMed: 21152443 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description

Targets

Abl ^[1] (Cell-free assay)	Src ^[1] (Cell-free assay)	c-Kit (D816V) ^[2] (Cell-free assay)	c-Kit (wt) ^[2] (Cell-free assay)
0.6 nM	0.8 nM	37 nM	79 nM

In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. ^[1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. ^[3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
M07ep210	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXG3NkBp	M1jQRmROW09?	M4DlSWlEPTB;MD6wNFAxPyEQvF2=	NG[zWmUyPzl3NkC4NC=>
K562	NGD2OphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUC3NkBp	M336R2ROW09?	MkjZTWM2OD1yLkCwNUDPxE1?	NGfRSI0yPzl3NkC4NC=>
M07e	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWLRZXQ6PzJiaB?=	NHfyRZNFVVOR	NFm2OGNKSzVyPUCuNFAyOiEQvF2=	MYKxO\|k2PjB6MB?=
ALL3	M{LOXWN6fG:2b4jpZ{BCe3OjeR?=	M1jWOFAvOc7:TR?=	MYi3NkBp	NYLESWs2TE2VTx?=	Mk\WTWM2OD1yLkCwNFQh\|ryP	MUWxPVg5QTV2MB?=
CML	M4nPT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2DaO\|IxKG2rbh?=	NWO0VHlNTE2VTx?=	NEDpS5JKSzVyPUCuNFAyKM7:TR?=	M4XkRlE6OjF7MEG2
BA/F3	MmjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXnlPHhOPzJiaB?=	MYfEUXNQ	NXTSVJpRUUN3ME22MlU5QSEQvF2=	MlvpNlMxQDh4NES=
BA/F3	NYjhfVQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkD1O\|IhcA>?	NV\qTZc4TE2VTx?=	MUTJcoR2[2W\|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDCZ5IuSWKuIF2zOVFVKG23dHHueEB4cXSqIFnDOVAhd2ZiMD6wNFA5O87:TR?=	M12xbFI{ODh6NkS0
BA/F3	NGH2fnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmjZO\|IhcA>?	MVLEUXNQ	NX3lTWpRUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEKlcj3BZowhf2m2aDDJR\|UxKG:oIECuNFA1Pc7:TR?=	MlXkNlMxQDh4NES=
BA/F3	NVzUXlBYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmTEO\|IhcA>?	MYfEUXNQ	Mlm4TY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy\|IHX4dJJme3OrbnegRoNzNUGkbDDUN\|E2USCvdYThcpQhf2m2aDDJR\|UxKG:oIEGuO\|E1\|ryP	MWmyN\|A5QDZ2NB?=
BA/F3	NUPXfFZqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mn[3O\|IhcA>?	NUHDS4h{TE2VTx?=	MnH3TY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTjR6NmOgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNFnPxE1?	MnvUNlM{ODF5MEO=
BA/F3	NX3zRlUyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkfmO\|IhcA>?	MVfEUXNQ	NVrWSWFGUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiRUK1OWshdXW2YX70JIF{e2W\|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxOzMQvF2=	MUGyN\|MxOTdyMx?=
BA/F3	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1HtclczKGh?	M2naT2ROW09?	M2XoRmlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEd{NUDFJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFUy\|ryP	MWWyN\|MxOTdyMx?=
BA/F3	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXrkZXRnPzJiaB?=	M3W1fmROW09?	MmPBTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhWTJ3MligcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwPO69VQ>?	MYmyN\|MxOTdyMx?=
BA/F3	NYS3UZpUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M33PflczKGh?	MmPRSG1UVw>?	Mnu3TY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTTN3OW[gcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNVPPxE1?	M2r2ZVI{OzBzN{Cz
BA/F3	M1e3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWK3NkBp	NEP2TFBFVVOR	NHTSTopKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z\|IHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFLDVk1CSkxiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECxPe69VQ>?	M3j3d\|I{OzBzN{Cz
BA/F3	NITCWlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MoPUO\|IhcA>?	NEf5bppFVVOR	MonVTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhYTJ3M1igcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNlPPxE1?	NW\a[WtnOjN\|MEG3NFM>
BA/F3	NUTWN5VOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWeyRXN7PzJiaB?=	M1zvfmROW09?	NWLVcHpkUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiVEOxOWkhdXW2YX70JIF{e2W\|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCzMlbPxE1?	MkLyNlM{ODF5MEO=
BA/F3	NFzxNJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWrZSXFHPzJiaB?=	NE\SOmlFVVOR	NF\BNFdKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHfyc5d1cCCLbnjpZol1cW:wIIfpeIghUUN3MDDv[kAzNjYQvF2=	M4HUflI{OzBzN{Cz
T cell	M1\1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MX23NkBp	M2TtbmROW09?	M2XySmlvcGmkaYTzJIFvfGliQ1SzMUBidmRiYX70bUBETDJ6LXnu[JVk\WRiVDDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMECz{txO	MUKxO\|E2PDVzMh?=
WiDr	NHW0bolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlfEO\|IhcA>?	M4S1d2ROW09?	MkLLTWM2OD1yLkC1NkDPxE1?	MljFNVU3OTV3MUK=
PC3	NWLHXYZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGfMc4Y4OiCq	NY\CRoxDTE2VTx?=	MonFTWM2OD1yLkCwPVQh\|ryP	M2\QT\|E2PjF3NUGy
MDA-MB-231	Mn\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MUO3NkBp	M3XySGROW09?	NEKwUXFKSzVyPUCuNFEzKM7:TR?=	MYixOVYyPTVzMh?=
Hs578T	NUXUfmMxS3m2b4TvfIlkKEG\|c3H5		M3XYVVczKGh?	NHPjWVJFVVOR	M2\YfmdKPTB;MD6wN{DPxE1?	MVuyOFAyPTN{Nx?=
HMEC	NIX6UFREgXSxdH;4bYMhSXO\|YYm=		NF34fYc4OiCq	MUPEUXNQ	MYTHTVUxRTFwODFOwG0>	MXGyOFAyPTN{Nx?=
DU145	M1r6PWN6fG:2b4jpZ{BCe3OjeR?=		NIO4W\|A4OiCq	Ml3zSG1UVw>?	MonOS2k2OD1yLkG2JO69VQ>?	MkHINlQxOTV\|Mke=
U251	MnTsR5l1d3SxeHnjJGF{e2G7		NVrZNmlJPzJiaB?=	NVfJeWI4TE2VTx?=	M1yzZ2dKPTB;Mj64NUDPxE1?	M{G0O\|I1ODF3M{K3
NCI60	MYrDfZRwfG:6aXOgRZN{[Xl?		MVG3NkBp	Ml\aSG1UVw>?	MlrDS2k2OD13Lkeg{txO	NFLTNZQzPDBzNUOyOy=>
MALME-3M	M1LEXGN6fG:2b4jpZ{BCe3OjeR?=		NF[xb5Q4OiCq	NWrldGg3TE2VTx?=	NFq2RVhIUTVyPU[uOlEh\|ryP	NX21WIwyOjRyMUWzNlc>
KM12	MX7DfZRwfG:6aXOgRZN{[Xl?		NULqe41TPzJiaB?=	NGXmfGRFVVOR	NGTRS\|FIUTVyPUeuOFQh\|ryP	MVGyOFAyPTN{Nx?=
SW620	NUn3NYZxS3m2b4TvfIlkKEG\|c3H5		NF:3XW84OiCq	NEPUSm5FVVOR	Mlv4S2k2OD16LkSzJO69VQ>?	MnvDNlQxOTV\|Mke=
RXF 393NL	MXvDfZRwfG:6aXOgRZN{[Xl?		NI\PN\|M1KGSjeYO=	NHTxcG5FVVOR	MUDJR\|UxRTBwMEKxO{DPxE1?	NXraU25NOjN{NUOwO\|Q>
LXFA 983L	Mlu3R5l1d3SxeHnjJGF{e2G7		NXPFWYx1PCCmYYnz	MlntSG1UVw>?	M3nZdGlEPTB;MD6wOVY2KM7:TR?=	NHPwWYMzOzJ3M{C3OC=>
PRXF DU145	M4TzcmN6fG:2b4jpZ{BCe3OjeR?=		M33IeVQh\GG7cx?=	NWPveVBRTE2VTx?=	M2fxb2lEPTB;MD6wOlI{KM7:TR?=	Mly1NlMzPTNyN{S=
PAXF 1657L	NFPNXGhEgXSxdH;4bYMhSXO\|YYm=		NGLiemg1KGSjeYO=	M4LlfWROW09?	MVrJR\|UxRTBwMUKxJO69VQ>?	MXOyN\|I2OzB5NB?=
CXF 1103L	MoWwR5l1d3SxeHnjJGF{e2G7		Mm\wOEBl[Xm\|	M4TBdGROW09?	NWTEUXZnUUN3ME20MlM3KM7:TR?=	M{PXflI{OjV\|MEe0
GXF251L	MVzDfZRwfG:6aXOgRZN{[Xl?		MlT2OEBl[Xm\|	MVrEUXNQ	MoHLTWM2OD1{LkK1JO69VQ>?	NFTOS48zOzJ3M{C3OC=>
NCI-H23	NWezcFBsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3zCb\|czKGh?	M1LLOWROW09?	M4\4TmlEPTB;Mj6yO{DPxE1?	NFza[YQzOzV{MUCyNC=>
HCT116	NULuTXVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXnxPWRnPzJiaB?=	MlnxSG1UVw>?	NYX1SmtZUUN3ME2yMlMh\|ryP	Ml;XNlM2OjFyMkC=
MCF7	MnLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVS3NkBp	NWXScItXTE2VTx?=	M2LBVGlEPTB;Mj61O{DPxE1?	MoTaNlM2OjFyMkC=
NCI-H460	M{TRSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYC3NkBp	NHPrfphFVVOR	MYPJR\|UxRThwOUmg{txO	MYWyN\|UzOTB{MB?=
DLD1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlHNO\|IhcA>?	NFfTV3lFVVOR	MkHJTWM2OD12Lk[g{txO	NWnLfoxkOjN3Nke5OlA>
NCI-H661	NVv0ZmhST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1;VU\|czKGh?	MoHjSG1UVw>?	MXfJR\|UxRTdwODFOwG0>	NXzGV201OjN3Nke5OlA>
A549	Ml[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUSwfWF7PzJiaB?=	MoThSG1UVw>?	M{fLUGlEPTB;OD6yJO69VQ>?	NELHd20zOzV4N{m2NC=>
U937	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MorlO\|IhcA>?	MYrEUXNQ	MoC5TWM2OD1zMj6yJO69VQ>?	NHvvcoEzOzV4N{m2NC=>
HEK293	NULsUG0xTnWwY4Tpc44hSXO\|YYm=	MoGxNVDDqM7:TR?=		M{fENGROW09?	NET1ZZFKdmS3Y3XzJIJqdmSrbnegZYZncW6rdImgeI8hcHWvYX6g[pVtdC2uZX7neIghUGm\|LYTh[4dm\CCPeYSxJItqdmG\|ZTDlfJBz\XO\|ZXSgbY4hUEWNMkmzJINmdGy\|IIfpeIghUUN3MDDv[kAxNjB4M988US=>	NWPzWXljOjJ5N{C2NVA>
HUVEC	M1;CV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWn3RZBjOC5zNdMg{txO	M2HDdVczKGh?	NXi3OIF1TE2VTx?=	NWXHOFJXUW6mdXPld{BidnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQzDjc{1kfWy2dYLl[EB4cXSqII\hd4N2dGG{IIPtc491cCCvdYPjcIUh[2WubIOgZZN{\XO\|ZXSgZZMhUW6qaXLpeIlwdiCxZjDj[YxtKGe{b4f0bEBifCByLkG1JJVO	MV:yNlg2Ozl7Mx?=
HUVEC	MYjGeY5kfGmxbjDBd5NigQ>?	MljSNVXDqM7:TR?=	MWS3NkBp	MUfEUXNQ	MUDJcoR2[2W\|IHHueIlidmerb3flcolkKGGldHn2bZR6KGmwIFjVWmVEKGOxLXP1cJR2emWmIIfpeIghfmG\|Y4XsZZIhe22xb4ToJI12e2OuZTDj[YxteyCjc4Pld5Nm\CCjczDJcohq[mm2aX;uJI9nKG6ndIfvdosh\m:{bXH0bY9vKGG2IEGuPEB1dyBzNTD1US=>	M1\KV\|IzQDV\|OUmz
Plasmodium falciparum	M1vtZmZ2dmO2aX;uJGF{e2G7	NHnKeGMyOMLizszN	NHTsVpEyPSCvaX6=	M3jCc2ROW09?	M3HvOGlvcGmkaYTzJHBt[XOvb3TpeY0h\mGuY3nwZZJ2dSCycn;sbYZmemG2aX;uJIJ6KGmwaHnibZRqdmdidHjlJGZ2dmO2aX;uJI9nKFCoQ1TQT\|EheHKxdHXpckB4cXSqIFnDOVAhd2ZiMT6xO:69VQ>?	M{nFdFI1PTVyM{Ow
PC3	M2ntb2Z2dmO2aX;uJGF{e2G7	Mmr2NE4yKM7:TR?=	NYG5V4RSPSCq	MoP1SG1UVw>?	MWTJcohq[mm2czDoeY1idiCSQ{OgZ4VtdCCjZHjld4lwdiCjdDCxNFAhdk1?	NYjUPJJzOTl2NkK5O\|U>
DU145	NY\5fGRDTnWwY4Tpc44hSXO\|YYm=	NF:0eVMxNjFizszN	NWjW[pZKPSCq	MnnSSG1UVw>?	MV;Jcohq[mm2czDoeY1idiCGVUG0OUBk\WyuIHHkbIV{cW:wIHH0JFExOCCwTR?=	NVvReWNqOTl2NkK5O\|U>
PC3	NFWzV3lMcW6jc3WgRZN{[Xl?	MXOwMlEh\|ryP	MYO1JIg>	MWPEUXNQ	NF;TPWhKdmirYnn0d{BkW3KlIHnuJIh2dWGwIGDDN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhW3KlIGm0NVYhdGW4ZXygZZQhOTByIH7N	MVOxPVQ3Ojl5NR?=
DU145	NV7LN2JkU2mwYYPlJGF{e2G7	MnzwNE4yKM7:TR?=	NUTZbWg6PSCq	MkXUSG1UVw>?	MnrETY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCGVUG0OUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhW3KlIGm0NVYhdGW4ZXygZZQhOTByIH7N	M2jMPFE6PDZ{OUe1
PC3	NEOyRYtMcW6jc3WgRZN{[Xl?	NUXmd4loOC5zIN88US=>	M4HYN\|UhcA>?	MXrEUXNQ	MUfJcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgSmFMKFl3N{[vXVU4PyCuZY\lcEBifCBzMECgcm0>	M4TBVFE6PDZ{OUe1
DU145	NHTFOWNMcW6jc3WgRZN{[Xl?	M33KXVAvOSEQvF2=	M{DmOFUhcA>?	MoS5SG1UVw>?	NEDCbXZKdmirYnn0d{BkW3KlIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCxZjDwbI9{eGixconsZZRm\CCIQVugXVU4Pi:\NUe3JIxmfmWuIHH0JFExOCCwTR?=	NVHhUZcyOTl2NkK5O\|U>
Huh7	MV\BcpRqfmm{YXygRZN{[Xl?	Mn;QNk42KM7:TR?=	NVHyO49sPCCmYYnz	M3fvfWROW09?	NXr6RlNZUW6qaXLpeJMhfmm{YXygd5Bz\WGmIHnuJGRmdme3ZTD2bZJ2ey2rbn\lZ5Rm\CCqdX3hckBJfWh5IHPlcIx{KGG\|c3Xzd4VlKGG\|IHHjZ5VufWyjdHnvckBw\iC4aYLhcEBmdn[nbH;w[UBxem:2ZXnuJJdqfGirbjDw[ZJqdnWlbHXhdkBz\Werb36gZZQhOi53IIXN	Moq3NVc{PjB4N{[=
C6/36	MmPkRY51cX[rcnHsJGF{e2G7	M4XkelIvPSEQvF2=	NFm2WJU1KGSjeYO=	MnfkSG1UVw>?	Mmf6TY5pcWKrdIOgeolz[Wxic4Dy[YFlKGmwIFTlcod2\SC4aYL1d{1qdm[nY4Tl[EBie2mjbjD0bYdmeiCvb4PxeYl1dyCFNj:zOkBk\WyuczDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25ib3[geolz[WxiZX72[YxweGVicILveIVqdiC5aYTobY4heGW{aX71Z4xm[XJicnXnbY9vKGG2IEKuOUB2VQ>?	NVXHS2JDOTd\|NkC2O\|Y>
U937	M2TMemZ2dmO2aX;uJGF{e2G7	NVzXPXJ[OSEQvF2=	NUf5bXRSOSCq	M3\HbmROW09?	MWrS[YR2[2W\|IHLhd4FtKFSQRnHsdIhiKHKnbHXhd4UhcW5iaIXtZY4hXTl\|NzDj[Yxtew>?	NYjtNVhZOTd4OESwPVk>
U937	NFKwW3RHfW6ldHnvckBCe3OjeR?=	NEjPWI4yKM7:TR?=	MXGxJIg>	NF;yTG5FVVOR	M2LoPXJm\HWlZYOgUHBUNWmwZIXj[YQhXE6IYXzwbIEhemWuZXHz[UBqdiCqdX3hckBWQTN5IHPlcIx{	MlX3NVc3QDRyOUm=
murine mast cell	MXnGeY5kfGmxbjDBd5NigQ>?	MYSxJO69VQ>?	NIfpdpozPCCq	NYTKc\|ZUTE2VTx?=	NXPDNYUyUW6qaXLpeJMh[W62aXflck1qdmS3Y3XkJGlNPiC\|ZXPy[ZRqd25iaX6gTYdGKHC{aX3l[EBud3W\|ZTDtZZN1KGOnbHzzJIF1KDFidV2=	MoTFNVc3QDRyOUm=
BV-173	MkHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnXoTWM2OD1yLkCwNFAxODFyOTFOwG0>	M4DOV3NCVkeHUh?=
K-562	NVLQVVhYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkTLTWM2OD1yLkCwNFAxODJ4NjFOwG0>	NITtT4ZUSU6JRWK=
BL-70	NIXLcFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIHCZ45KSzVyPUCuNFAxODByOEKyJO69VQ>?	M{nENXNCVkeHUh?=
EM-2	NXPyXIYyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfQSJJKSzVyPUCuNFAxODBzMEig{txO	MlrZV2FPT0WU
LAMA-84	MlzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M336V2lEPTB;MD6wNFAxODN{MTFOwG0>	NV7rflBbW0GQR1XS
MEG-01	NYGxU3oxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTBwMECwNFA6QCEQvF2=	NEmzTYtUSU6JRWK=
EoL-1-cell	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUf1fpgzUUN3ME2wMlAxODBzM{Gg{txO	Ml\3V2FPT0WU
CTV-1	MlyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWnJR\|UxRTBwMECwNFQxPCEQvF2=	M164THNCVkeHUh?=
TE-15	M{\sWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXfIdlczUUN3ME2wMlAxPTh7IN88US=>	MkewV2FPT0WU
NOS-1	NFfhOGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHGwVZFKSzVyPUCuNFA3OTNizszN	NFzIV25USU6JRWK=
D-336MG	MmHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTBwMEC2N{DPxE1?	M3PRPXNCVkeHUh?=
LB1047-RCC	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYr5OHRLUUN3ME2wMlAxQTh7IN88US=>	NV;EPFUyW0GQR1XS
LB996-RCC	MmCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWDX[HNGUUN3ME2wMlAxQTlzIN88US=>	M1;o[XNCVkeHUh?=
SW982	M4CxWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUDNOVlZUUN3ME2wMlAyOTF3IN88US=>	MXnTRW5ITVJ?
TK10	MmnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGf2WlJKSzVyPUCuNFEyPzRizszN	NWC2c5VzW0GQR1XS
A704	NED1dlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIm2[nNKSzVyPUCuNFE1QTFizszN	MYrTRW5ITVJ?
TE-8	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGLpXHhKSzVyPUCuNFE2PzZizszN	NUnVeldZW0GQR1XS
DOHH-2	MoKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NViyT41GUUN3ME2wMlAyPzF7IN88US=>	M2\tU3NCVkeHUh?=
HOP-62	NHLBUohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2fkNWlEPTB;MD6wNVg{PCEQvF2=	MVPTRW5ITVJ?
TE-12	M1jmXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIC5ZYpKSzVyPUCuNFE5PjFizszN	NWLR[XUxW0GQR1XS
KGN	NX;hboxRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYi0Z5ZRUUN3ME2wMlAyQTR{IN88US=>	M4\EWXNCVkeHUh?=
NCI-H1648	NF33e\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmTITWM2OD1yLkCyNFEyKM7:TR?=	MlvZV2FPT0WU
OS-RC-2	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTBwMEKwN{DPxE1?	NETwNG1USU6JRWK=
GB-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4H2fmlEPTB;MD6wNlE2PyEQvF2=	M3L6U3NCVkeHUh?=
RXF393	NImzOYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTBwMEKzOVch\|ryP	M1npbnNCVkeHUh?=
LC-2-ad	Mn;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2DsVmlEPTB;MD6wNlU5PiEQvF2=	M{\rbHNCVkeHUh?=
KS-1	NHexV2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEHwUFZKSzVyPUCuNFI4OyEQvF2=	MkPxV2FPT0WU
ETK-1	NXr3fItQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVP5ZpBmUUN3ME2wMlAzQDN{IN88US=>	MYjTRW5ITVJ?
SW954	NWfhUFk6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;OS4RKSzVyPUCuNFI6OjdizszN	MXHTRW5ITVJ?
Becker	MoSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnqwTWM2OD1yLkCzNFA{KM7:TR?=	M3jWWnNCVkeHUh?=
MZ1-PC	NUiz[ZE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2TVdGlEPTB;MD6wN\|EyQSEQvF2=	MX7TRW5ITVJ?
ES6	NVPxeIh4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEHJSZJKSzVyPUCuNFMyQTNizszN	NGnnbnBUSU6JRWK=
KURAMOCHI	M2LIW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MY\JR\|UxRTBwMEO0PFch\|ryP	MYrTRW5ITVJ?
CGTH-W-1	Mny1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnn5TWM2OD1yLkCzOVQ5KM7:TR?=	M2HXbXNCVkeHUh?=
VA-ES-BJ	M2K5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmLFTWM2OD1yLkCzPVAzKM7:TR?=	NV21eGhTW0GQR1XS
LXF-289	M2r5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1vRNmlEPTB;MD6wN\|k2PiEQvF2=	M3:wSHNCVkeHUh?=
MPP-89	NXTJbZdyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEHCZ\|VKSzVyPUCuNFQxPDlizszN	MoXJV2FPT0WU
SW872	M3vmTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYi2OI1pUUN3ME2wMlA1OTZzIN88US=>	M3H3OXNCVkeHUh?=
SNB75	NFn1XmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTBwMES0N\|Uh\|ryP	MlP0V2FPT0WU
PSN1	Mn3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRTBwMES0O\|Qh\|ryP	NFLrV4FUSU6JRWK=
LB831-BLC	NVzsfYg4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmrhTWM2OD1yLkC0OlA6KM7:TR?=	NYmwNVhEW0GQR1XS
MFH-ino	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3HSPWlEPTB;MD6wOFczPCEQvF2=	M1m0enNCVkeHUh?=
TGBC24TKB	NYrWclQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYr6N2NkUUN3ME2wMlA1PzZzIN88US=>	M1TLTHNCVkeHUh?=
A388	NULqbY1lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV3jV2NEUUN3ME2wMlA2ODl3IN88US=>	NYK0c3BIW0GQR1XS
BB30-HNC	NYfSfVFuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUfNOGxoUUN3ME2wMlA2PDN5IN88US=>	M2nSeHNCVkeHUh?=
GI-ME-N	NWTENoh7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTBwME[xNVgh\|ryP	M37yc3NCVkeHUh?=
TGBC1TKB	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnW1TWM2OD1yLkC2NVY1KM7:TR?=	MUHTRW5ITVJ?
TE-10	M{TSNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGn3RpRKSzVyPUCuNFY{PTdizszN	MV\TRW5ITVJ?
A498	NWXwTIZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTBwMEeyPFQh\|ryP	MkfUV2FPT0WU
TE-11	NUL2Upc4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTBwMEe4OVgh\|ryP	M{jxenNCVkeHUh?=
BB65-RCC	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTBwMEiyNlch\|ryP	MkLYV2FPT0WU
C2BBe1	NWrrW3d5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2Hx[WlEPTB;MD6wPFMxQCEQvF2=	NHf3d\|JUSU6JRWK=
NCI-H747	Mo\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTBwMEizOlIh\|ryP	NFS2PIxUSU6JRWK=
IST-MES1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoKyTWM2OD1yLkC4OVUzKM7:TR?=	NGHVTZBUSU6JRWK=
KALS-1	NIHEepFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlrrTWM2OD1yLkC5OFkh\|ryP	NHfPN25USU6JRWK=
GCIY	M2XUZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlXITWM2OD1yLkC5OlU3KM7:TR?=	MYPTRW5ITVJ?
RL95-2	MnSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTBwMUCzPEDPxE1?	MYnTRW5ITVJ?
TE-1	MlLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVXtVZllUUN3ME2wMlExPTRizszN	NEHXeZNUSU6JRWK=
NCI-H1355	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYrs[pV7UUN3ME2wMlEyODJ6IN88US=>	MnnXV2FPT0WU
SW962	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M17tR2lEPTB;MD6xNVI6OiEQvF2=	MnrOV2FPT0WU
KLE	NYTCblFTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGrmOIFKSzVyPUCuNVE{OTdizszN	MmnkV2FPT0WU
MC116	NVzSXHhxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnfGTWM2OD1yLkGxOFEh\|ryP	MUHTRW5ITVJ?
NMC-G1	MkHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3jzWGlEPTB;MD6xNVYxPiEQvF2=	NGK3Xo9USU6JRWK=
KU812	NFvSd3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnf5TWM2OD1yLkGxPFg{KM7:TR?=	NX7rPYdFW0GQR1XS
COLO-829	NIPBN49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWfJS4tuUUN3ME2wMlEzOjF\|IN88US=>	NWDD[Y9bW0GQR1XS
NTERA-S-cl-D1	NXfiZndZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVfPcphJUUN3ME2wMlEzOjh\|IN88US=>	MWjTRW5ITVJ?
IST-MEL1	MoP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWPJR\|UxRTBwMUO0OUDPxE1?	MlH5V2FPT0WU
MLMA	M1rLV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRTBwMUSwN\|Ih\|ryP	M3TWNHNCVkeHUh?=
LS-123	NEfRfo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXrhW4dYUUN3ME2wMlE1ODZ2IN88US=>	NYjpOlNXW0GQR1XS
LB2518-MEL	NIC2[npIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnHNlNHUUN3ME2wMlE1OTZ{IN88US=>	MXjTRW5ITVJ?
NB69	NFfiZ3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTBwMUS0N\|Yh\|ryP	MlG5V2FPT0WU
8-MG-BA	MlHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Moe4TWM2OD1yLkG1OFU5KM7:TR?=	NYG1XHExW0GQR1XS
K5	M4LCdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkjSTWM2OD1yLkG2OFg6KM7:TR?=	MYHTRW5ITVJ?
KINGS-1	MnTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\hUWRKSzVyPUCuNVY3PjZizszN	MknkV2FPT0WU
SF268	M4PKTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVvhR2hFUUN3ME2wMlE4PDB2IN88US=>	NGCxflhUSU6JRWK=
PF-382	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH7re2lKSzVyPUCuNVc3PzhizszN	M4qxbnNCVkeHUh?=
SH-4	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;kbmV3UUN3ME2wMlE5PDF\|IN88US=>	MYfTRW5ITVJ?
NALM-6	NXnrU5dlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{TpZWlEPTB;MD6xPVI6PSEQvF2=	Ml\3V2FPT0WU
CP66-MEL	MmrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXHvXIoxUUN3ME2wMlE6PTNzIN88US=>	NH;scXFUSU6JRWK=
697	M4L1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYi1R\|ZzUUN3ME2wMlE6QTh5IN88US=>	MmruV2FPT0WU
CP67-MEL	M1zHPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH;GcVFKSzVyPUCuNlA1QDhizszN	NXPIfnplW0GQR1XS
DSH1	MmnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlG4TWM2OD1yLkK0NFAyKM7:TR?=	MnjnV2FPT0WU
HCE-4	NIC3[WZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTBwMk[0N\|kh\|ryP	M3P4TXNCVkeHUh?=
MZ2-MEL	NUDvb5NjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4SyVWlEPTB;MD6yPFU{PyEQvF2=	M1TSSHNCVkeHUh?=
BL-41	NGri[5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGP3W5VKSzVyPUCuNlkyOjNizszN	Mm\MV2FPT0WU
HUTU-80	MlrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG\qUIhKSzVyPUCuN\|E1OiEQvF2=	NFvSRWhUSU6JRWK=
LOXIMVI	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV70bGRZUUN3ME2wMlMyPTB\|IN88US=>	NYXC[o56W0GQR1XS
no-10	M4K5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NImwU4NKSzVyPUCuN\|E6OzFizszN	M4LQU3NCVkeHUh?=
KARPAS-422	MnXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2q4WWlEPTB;MD6zN\|k6PyEQvF2=	MXvTRW5ITVJ?
SW684	NVnne3FNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn;CTWM2OD1yLkO0PVgh\|ryP	NXHrNIJmW0GQR1XS
SF126	M4HhSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4j4b2lEPTB;MD6zOVQyKM7:TR?=	Ml3wV2FPT0WU
D-263MG	NXTUWGtoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{nGNmlEPTB;MD6zOlIzPCEQvF2=	NEmxZXhUSU6JRWK=
OVCAR-4	M2f1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH7xWo1KSzVyPUCuN\|c1OzNizszN	NF7vWodUSU6JRWK=
BB49-HNC	MnXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHPYNIFKSzVyPUCuN\|g2QTlizszN	NVr6PIx2W0GQR1XS
ONS-76	NEPKeo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGO1dnJKSzVyPUCuOFI6PTFizszN	NYDOSFN1W0GQR1XS
MZ7-mel	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGfs[JFKSzVyPUCuOFc6OTFizszN	NH71V25USU6JRWK=
RCC10RGB	NHXOc2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4O1TmlEPTB;MD60PVEyKM7:TR?=	NVftd4tCW0GQR1XS
BOKU	NF7ZXFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{H1V2lEPTB;MD60PVE{OyEQvF2=	MX\TRW5ITVJ?
no-11	NGDZbpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVjYTVFCUUN3ME2wMlUxOjJ6IN88US=>	NWPkS4NxW0GQR1XS
IST-SL2	NYe5W3lJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\jcmlEPTB;MD61NFMxOiEQvF2=	MXrTRW5ITVJ?
RKO	M33yZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWHtbYF2UUN3ME2wMlUzQTZ4IN88US=>	MorzV2FPT0WU
HT-144	Mnq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml;ZTWM2OD1yLkWzOlA6KM7:TR?=	MYLTRW5ITVJ?
NCI-H446	M2LsUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NITqSllKSzVyPUCuOlI4PiEQvF2=	M3v1RXNCVkeHUh?=
QIMR-WIL	M2\ofGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnrQTWM2OD1yLkewOlI6KM7:TR?=	MWDTRW5ITVJ?
MHH-PREB-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTBwN{S0Olkh\|ryP	NYT2WoZ1W0GQR1XS
EW-16	NULveop3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;2cHZ{UUN3ME2wMlc3OTd6IN88US=>	M1vReXNCVkeHUh?=
EW-24	M3f5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTBwN{ixOlUh\|ryP	MljXV2FPT0WU
LB373-MEL-D	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWfaRVdJUUN3ME2wMlgzPTB6IN88US=>	MknuV2FPT0WU
TE-9	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEH5UFhKSzVyPUCuPFc2OzJizszN	NGjUZXhUSU6JRWK=
A3-KAW	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXHXdo9TUUN3ME2wMlk5PDV{IN88US=>	NXLqcI9YW0GQR1XS
A101D	NITz[WtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml;BTWM2OD1zLkCzNFQ{KM7:TR?=	NETsN4xUSU6JRWK=
OCUB-M	Mn;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFvlRYxKSzVyPUGuNFQ1OTJizszN	MWjTRW5ITVJ?
ES4	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLaTWM2OD1zLkC1NVQ2KM7:TR?=	NIn2UINUSU6JRWK=
TE-6	NH3DdWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYewV4JEUUN3ME2xMlIyOjJ4IN88US=>	MlXCV2FPT0WU
D-502MG	NWjke3VLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MofYTWM2OD1zLkKzN\|c3KM7:TR?=	NXHuTW5wW0GQR1XS
KNS-42	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4HaUGlEPTB;MT6yOFQyOiEQvF2=	MmXYV2FPT0WU
SNU-C2B	NEHWU\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3[5NmlEPTB;MT6zNFU5QSEQvF2=	MV;TRW5ITVJ?
NCI-H1838	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4XueWlEPTB;MT6zNFc{OyEQvF2=	Mmi1V2FPT0WU
NKM-1	NYK1NVBQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXLJR\|UxRTFwM{C4OVkh\|ryP	NGPwNldUSU6JRWK=
GI-1	NH3LR25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRTFwM{[yNkDPxE1?	MUHTRW5ITVJ?
NB5	M3fyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTFwM{m4Nlch\|ryP	MUXTRW5ITVJ?
CAS-1	NEnIZYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mof1TWM2OD1zLkSwPVkzKM7:TR?=	MmT1V2FPT0WU
HCE-T	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYW4PVZmUUN3ME2xMlU3PzF2IN88US=>	Mn23V2FPT0WU
SBC-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnTHTWM2OD1zLkW3PVg1KM7:TR?=	NFnjPXJUSU6JRWK=
JiyoyeP-2003	NHLjSmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTFwN{O0OlYh\|ryP	M4XKcnNCVkeHUh?=
TE-5	NGjvZYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn7PTWM2OD1zLke5NVM6KM7:TR?=	M2ryfnNCVkeHUh?=
CAN	NWqzeZdsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnXvTWM2OD1zLkiyNlUzKM7:TR?=	MULTRW5ITVJ?
SK-UT-1	NHPFS4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoPLTWM2OD1{LkG2Olk{KM7:TR?=	MXXTRW5ITVJ?
JVM-2	NEfXRYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXuPWZKSzVyPUKuN\|YzQDRizszN	M4fnVnNCVkeHUh?=
LB771-HNC	M4LYUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NU\4VlVIUUN3ME2yMlU4PTVzIN88US=>	MkTUV2FPT0WU
NCCIT	M{fJXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWf2T5g4UUN3ME2yMlg3PjF4IN88US=>	NXfMTIxpW0GQR1XS
NCI-H2126	NVzZSZhVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRTJwOEe1OVIh\|ryP	NHm2XFRUSU6JRWK=
Calu-6	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnfjTWM2OD1\|LkC1O\|QyKM7:TR?=	MXLTRW5ITVJ?
SK-LMS-1	NYLXWXJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmXrTWM2OD1\|LkGxPFg3KM7:TR?=	MkTlV2FPT0WU
ARH-77	NIjs[pFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NITydo5KSzVyPUOuOFY6OTVizszN	NF\jclRUSU6JRWK=
NB17	MmHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknWTWM2OD1\|Lk[zPFQ4KM7:TR?=	MnzTV2FPT0WU
A253	NWHPTnV5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWHpWphJUUN3ME2zMlc{OjR4IN88US=>	NX;3NVQ3W0GQR1XS
OPM-2	NH7uVWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVHMR5lJUUN3ME20MlI4Pjh3IN88US=>	M4naNnNCVkeHUh?=
MV-4-11	Mk\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{j6cGlEPTB;ND6zOlQ2PCEQvF2=	NVfOfGVrW0GQR1XS
SR	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTRwNEm5OVQh\|ryP	MWLTRW5ITVJ?
KG-1	M{DKU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE[wUFBKSzVyPUSuOlA5PDVizszN	MkjXV2FPT0WU
OCI-AML2	Mn3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRTVwOE[xOVQh\|ryP	NWLDSZh{W0GQR1XS
D-247MG	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{\FOGlEPTB;Nj6xNlUyQSEQvF2=	Mn3VV2FPT0WU
DJM-1	MmXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGrBPJZKSzVyPU[uOFg2PThizszN	NGHOPWZUSU6JRWK=
RPMI-6666	M4XBS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2\5SmlEPTB;Nz6yO\|A3PyEQvF2=	MorJV2FPT0WU
KARPAS-45	NWrxZm06T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTdwNUG2O\|Eh\|ryP	NEmybopUSU6JRWK=
LP-1	NFnEbFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTdwNUS3PFIh\|ryP	M{nyVHNCVkeHUh?=
RS4-11	Mmi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{nQfGlEPTB;Nz62OVc5PyEQvF2=	NHvEbotUSU6JRWK=
DU-4475	M2fmO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NITYU2hKSzVyPUiuNlE3PTJizszN	NGP0bmZUSU6JRWK=
MONO-MAC-6	MonpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{X2R2lEPTB;OD6yO\|A3PiEQvF2=	M2DSOnNCVkeHUh?=
NCI-SNU-16	Mlz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml3DTWM2OD16LkW2NVI5KM7:TR?=	MnzUV2FPT0WU
SJSA-1	NULvOoNyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXPPdm5IUUN3ME24MlczQDB3IN88US=>	M3XZcHNCVkeHUh?=
MMAC-SF	NUTwXVFCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnvnTWM2OD16Lke5N\|A4KM7:TR?=	MXvTRW5ITVJ?
SK-NEP-1	M1fYOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIPrZ2JKSzVyPUiuPFkyPTVizszN	M1ftWXNCVkeHUh?=
J-RT3-T3-5	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEjObJFKSzVyPUiuPVY2OjlizszN	NFTIdZFUSU6JRWK=
SKM-1	MnTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NY\3S4VGUUN3ME25MlAyPzN2IN88US=>	MnzQV2FPT0WU
LB2241-RCC	NGHwe21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYLRdWo6UUN3ME25MlAzODF{IN88US=>	MoLIV2FPT0WU
SIG-M5	M33xemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mo\MTWM2OD17LkCyOFk{KM7:TR?=	MWHTRW5ITVJ?
EVSA-T	NFPHcHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTlwMke3PVMh\|ryP	M{i3OXNCVkeHUh?=
GT3TKB	M{\1cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUjPdpRYUUN3ME25MlM2PTR4IN88US=>	NHTHS2VUSU6JRWK=
NB6	NHXzU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVTNe4dMUUN3ME25MlkzOjV7IN88US=>	MnfqV2FPT0WU
EHEB	NEK2XJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGO5UHVKSzVyPUGwMlA3PTZizszN	M1Tld3NCVkeHUh?=
HEL	MknGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml7DTWM2OD1zMD60O\|c3KM7:TR?=	MV;TRW5ITVJ?
ALL-PO	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTFyLke5N\|gh\|ryP	M3;mdnNCVkeHUh?=
TGW	NH7JcnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGLnN2xKSzVyPUGxMlI5OjhizszN	MVjTRW5ITVJ?
BC-3	MkTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEHP[XlKSzVyPUGyMlEyOzhizszN	NHfmU\|ZUSU6JRWK=
IA-LM	NGrDTnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1HTNGlEPTB;MUKuOFQ1PSEQvF2=	MYXTRW5ITVJ?
UACC-257	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFLFOodKSzVyPUGyMlkyQThizszN	NVLUd2RMW0GQR1XS
KP-N-YS	M{DQW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXnDNoc1UUN3ME2xNk46Ojh\|IN88US=>	MX\TRW5ITVJ?
Raji	M1v1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTF\|Lke0PVch\|ryP	MX;TRW5ITVJ?
SF539	NGXXbJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3ezbWlEPTB;MUOuPFU2PyEQvF2=	M{LBVnNCVkeHUh?=
DMS-153	NIPGdZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MULJR\|UxRTF2LkCwNlgh\|ryP	Mlf6V2FPT0WU
L-540	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFTaU2RKSzVyPUG1MlA3PzJizszN	NIXv[ohUSU6JRWK=
MN-60	Mki3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M33jVGlEPTB;MUWuNVk4QSEQvF2=	M3z4ZnNCVkeHUh?=
RPMI-8866	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXoXZJYUUN3ME2xO{41PDV2IN88US=>	NYTmcnBJW0GQR1XS
NCI-H510A	NUC5XHh5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmq2TWM2OD1zOT6zPVc{KM7:TR?=	NV\KNIpMW0GQR1XS
NB13	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH62N4NKSzVyPUG5MlQ5PzdizszN	M4TYT3NCVkeHUh?=
HAL-01	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWfJR4E6UUN3ME2xPU44PTR\|IN88US=>	NFm3WHFUSU6JRWK=
NCI-H720	Mn7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4XqU2lEPTB;MkCuNlc{OyEQvF2=	M{nKRnNCVkeHUh?=
REH	NH3CSo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn;STWM2OD1{MD62N\|U4KM7:TR?=	NHrN[GVUSU6JRWK=
KNS-81-FD	MlPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTJ\|LkG0OkDPxE1?	MVfTRW5ITVJ?
HC-1	MoXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWTNNpJNUUN3ME2yOE42PTVzIN88US=>	MU\TRW5ITVJ?
NCI-H2141	NWW5OlBjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEf3cIdKSzVyPUK0Mlc4PTRizszN	NGnRZ3NUSU6JRWK=
MOLT-4	M3HETmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTJ4Lk[3OVMh\|ryP	M4D5VXNCVkeHUh?=
OMC-1	NFS1dnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWHJNFA6UUN3ME2yO{4yPDJ{IN88US=>	NFz6dZlUSU6JRWK=
LC-1F	M1iwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmewTWM2OD1{Nz6zNlQ2KM7:TR?=	NVP5eGlHW0GQR1XS
NCI-H1304	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml23TWM2OD1{OD6xOlI5KM7:TR?=	M3XxWXNCVkeHUh?=
BC-1	NGDwPXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{jqeGlEPTB;MkiuOlUyKM7:TR?=	NHrm[mNUSU6JRWK=
NCI-H64	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmfnTWM2OD1{OT62NlU{KM7:TR?=	Mon0V2FPT0WU
MOLT-16	MorjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHj4dWxKSzVyPUK5MlYzQTJizszN	NH60W\|lUSU6JRWK=
U-87-MG	MojiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHLZR3BKSzVyPUOwMlc3PiEQvF2=	MkXjV2FPT0WU
GAK	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEjkO3BKSzVyPUOxMlI3QDZizszN	M3myU3NCVkeHUh?=
ES8	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVWxdHF2UUN3ME2zNk4yOjV{IN88US=>	NGPyXHZUSU6JRWK=
HCC1599	NFvNUFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTiTWM2OD1\|Mj6zN\|I2KM7:TR?=	M{DiV3NCVkeHUh?=
EB-3	M4XncGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3P3S2lEPTB;M{SuN\|EyPyEQvF2=	MkHiV2FPT0WU
HCC1187	MlPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{PLO2lEPTB;M{WuPFA2OiEQvF2=	NWTxOmM3W0GQR1XS
SK-PN-DW	M1fwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NULzV2puUUN3ME2zOk4yQTR\|IN88US=>	M1PLbXNCVkeHUh?=
JVM-3	NXvGSnl6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYLZUJF6UUN3ME2zO{4zOzN6IN88US=>	MmTjV2FPT0WU
HCC2157	Mn3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVnRT3BMUUN3ME2zO{46QTR4IN88US=>	MkHrV2FPT0WU
A4-Fuk	M4ntXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnLNTWM2OD1\|OD6xNFA6KM7:TR?=	MW\TRW5ITVJ?
COR-L279	M13RZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHfyWpFKSzVyPUSwMlI5PTFizszN	NUXkU5pYW0GQR1XS
DEL	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVX6ZXU{UUN3ME20NU46ODh4IN88US=>	M1;RXnNCVkeHUh?=
NCI-H1395	NITrSVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\CWZpKSzVyPUSyMlAyPjNizszN	MX;TRW5ITVJ?
MHH-NB-11	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHWzfmxKSzVyPUSzMlA5OThizszN	NF;lPXlUSU6JRWK=
NCI-H2107	Mo[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1;WTGlEPTB;NEOuOFg1PiEQvF2=	MnjLV2FPT0WU
NEC8	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTR2LkOzOkDPxE1?	M{TyOHNCVkeHUh?=
COLO-684	NEDDZnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnTuTWM2OD12Nj6yNlU5KM7:TR?=	M3XkeXNCVkeHUh?=
LS-411N	M1\xWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVi1XoZCUUN3ME20PE41PzR6IN88US=>	M321PXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	phospho-c-Abl(Tyr245) / phospho-c-Src(Tyr416); PubMed: 23049975 PLoS One Protein levels of phosphorylated c-Abl (Tyr245), c-Abl, phosphorylated c-Src (Tyr416), c-Src, and GAPDH in NSC-34 cells overexpressing human wild-type or mutant SOD1s treated with various concentrations of dasatinib were measured by western blot. Cells were cultured in serum-free culture medium with doxycycline (Dox, 2 µg/ml), and western blot was performed at 24 h after dasatinib addition. p27 / p21; PubMed: 20145167 Clin Cancer Res Dasatnib induced cell cycle arrest. Dasatinib induced growth arrest, shown as a cell cycle distribution graph in the lower panel, correlated with increased p27 and p21 levels. Western blotting for levels of p27 and p21 was performed on protein lysates of THP-1 cells treated for 48 hours with indicated doses of dasatinib or DMSO. Detection of actin served as control for comparable protein loading. p-FAK / p-STAT3; PubMed: 23721490 BMC Cancer The effect of dasatinib in cell signalling. Western blot analysis with phosphorylated Src, FAK, Stat3, Akt and MAPK in HCC cell lines after 24 hours treatment of dasatinib. The cell lines were arranged according to their IC50 to dasatinib. The top three were most sensitive, the bottom 3 were least sensitive. cleaved caspase 3; PubMed: 20145167 Clin Cancer Res Dasatinib induced apoptosis. Dasatinib causes apoptosis in Mo7e-KitD816H cells as detected by cleavage of caspase 3. Whole cell lysates were prepared after 24 hour treatment with dasatinib. Caspase 3 and cleaved capase 3 were analyzed by western blotting. Actin serves as loading control.	23049975 20145167 23721490
Growth inhibition assay	IC50; PubMed: 23721490 BMC Cancer 9 HCC cell lines were exposed to the dedicated concentrations of dasatinib for 72 hours, and IC50 was tested by MTS. Results represent the mean (± SD) of three experiments.	23721490
Immunofluorescence	SRC / Met; PubMed: 26517812 Oncotarget Immunocytochemistry of SRC and Met localization. Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in A. LN-18 and B. U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively. F-actin / Actinin-4 / Paxillin; PubMed: 31053734 Nat Commun Conditionally immortalized differentiated podocytes treated for one-hour with 2 µM kinase inhibitor were stained for F-actin (phalloidin), α-actinin-4, paxillin, and nuclei (Hoechst 33342) to assess cytoskeletal and focal adhesion architecture (scale bars = 50 µm). Podocytes treated with dasatinib showed a marked decrease in cell-to-cell contacts, cell size and number of focal adhesions. α-tubulin; PubMed: 26517812 Oncotarget Combination of dasatinib and crizotinib impedes the formation of the α-tubulin-labeled mitotic spindle. LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm.	26517812 31053734
ELISA	TNF-α; PubMed: 17684099 Proc Natl Acad Sci U S A U937 cells were differentiated with vitamin D3, pretreated with the indicated concentrations of drugs for 1 h and stimulated with LPS for 6 h. TNF-α secretion was measured by ELISA. The graph shows the mean of two experiments done in duplicate. E-selectin; PubMed: 31110200 Sci Rep HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of E-selectin was determined using ELISA (n = 3, ±SEM). VCAM-1; PubMed: 31110200 Sci Rep HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of VCAM-1 was determined using ELISA (n = 3, ±SEM).	17684099 31110200

In vivo

Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. ^[3]

Protocol

Kinase Assay: ^[1]	- Collapse Kinase autophosphorylation assays: Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research: ^[1]	- Collapse Cell lines: Ba/F3 cell lines Concentrations: ~32 nM Incubation Time: 72 hours Method: Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I. (Only for Reference)
Animal Research: ^[3]	- Collapse Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC) Dosages: 30 mg/kg Administration: Administered via i.p. (Only for Reference)

References

[4] Dargart JL, et al. Antiviral Res. 2012, 95(1), 49-56.

- Collapse

Solubility (25°C)

In vitro	DMSO	98 mg/mL (200.81 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dasatinib SDF

Molecular Weight	488.01
Formula	C₂₂H₂₆ClN₇O₂S
CAS No.	302962-49-8
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	BMS-354825
Smiles	CC1=NC(=CC(=N1)N2CCN(CCO)CC2)NC3=NC=C(S3)C(=O)NC4=C(Cl)C=CC=C4C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04063124	Suspended	Drug: Dasatinib + Quercetin	Alzheimer Disease	The University of Texas Health Science Center at San Antonio\|Mayo Clinic	February 14 2020	Phase 1\|Phase 2
NCT04155411	Recruiting	Drug: Dasatinib	Dasatinib\|BCR-ABL\|Chronic Myeloid Leukemia	Shenzhen Second People''s Hospital	December 1 2019	Phase 4
NCT04115059	Recruiting	Drug: Dasatinib	Waldenstrom Macroglobulinemia\|DASATINIB	Jorge J. Castillo MD\|Bristol-Myers Squibb\|Dana-Farber Cancer Institute	November 4 2019	Phase 1
NCT03318770	Not yet recruiting	Drug: Dasatinib and blinatumomab	Acute Lymphoblastic Leukemia	Gruppo Italiano Malattie EMatologiche dell''Adulto	December 2018	--
NCT03625388	Recruiting	Drug: Dasatinib	Chronic Myelogenous Leukemia	Hikma Pharmaceuticals LLC	November 5 2018	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
what’s the difference between S1021 and S7782? Which one is better for in vivo studies?
Answer:
Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).
Question 2:
Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?
Answer:
Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Pan Src Inhibitor

Saracatinib (AZD0530) : Pan-Src inhibitor, IC50=2.7-11 nM for c-Src/c-Yes/Fyn/Lyn/Blk/Fgr/Lck.
FDA-approved Src Inhibitor

Bosutinib (SKI-606) : Approved by FDA for Ph+ chronic myelogenous leukemia (CML).
Newest Src Inhibitor

PP1 : Potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
Classic Src Inhibitor

KX2-391 : The first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.

Related Src Products

Dasatinib Monohydrate ^New

Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.
SU6656 ^New

SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.
PX-478 2HCl ^New

PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. PX-478 2HCl induces apoptosis and has anti-tumor activity. Phase 1.
Saracatinib (AZD0530)

Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Saracatinib induces autophagy. Phase 2/3.

Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.
Bosutinib (SKI-606)

Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively. Bosutinib also effectively decreases the activity of PI3K/AKT/mTOR, MAPK/ERK and JAK/STAT3 signaling pathways by blocking the phosphorylation levels of p-ERK, p-S6, and p-STAT3. Bosutinib promotes autophagy.
KX2-391（Tirbanibulin）

KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. Phase 2.
PP1

PP1 is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
PP2

PP2, a Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM in cell-free assays, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.
WH-4-023

WH-4-023 is a potent and orally active Lck/Src inhibitor with IC50s of 2 nM and 6 nM in cell-free assays, respectively. Exhibits >300-fold selectivity against p38α and KDR. Also potently inhibits SIK (IC50 values are 10, 22 and 60 nM for SIK 1, 2 and 3 respectively) and displays selectivity over a range of closely related kinases.
Ibrutinib (PCI-32765)

Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc. Ibrutinib is applicable as a Btk ligand in the synthesis of a series of PROTACs including P13I.

Choose Your Country or Region

By Signaling Pathways

By product type

Dasatinib